Is re-treatment possible with anti-CD38 therapies?

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MDПодробнее

Novel Therapies / New Trials - Kidney TransplantПодробнее

Phase III ASPIRE study and prospective anti-CD38 therapy for myelomaПодробнее

Mechanistic insights into the resistance to anti-CD38 therapyПодробнее

Anti-CD38 immunotherapy treatment for multiple myelomaПодробнее

CD38: a promising target for multiple myeloma antibody therapyПодробнее

The impact of the addition of anti-CD38 monoclonal antibodies to the frontline treatment of myelomaПодробнее

A retrospective study analyzing outcomes of patients with anti-CD38 refractory myelomaПодробнее

The Impact of CD38-Targeted Therapy in Multiple MyelomaПодробнее

Managing patients with R/R DLBCL who are not suitable candidates for autoSCTПодробнее

Current research on anti-CD38 CAR T-cell therapiesПодробнее

Safety Profile of Anti-CD38 Monoclonal Antibodies in MMПодробнее

Anti CD38 and anti SLAMF7 Therapeutics: Are they ready to go upfront?Подробнее

Anti-CD38 monoclonal antibodies – a new drug class for treating myelomaПодробнее

CD38 Antibodies in Multiple Myeloma: What Next?Подробнее

Dr. Noopur Raje Discusses Anti-CD38 Antibodies in MyelomaПодробнее

Stem cell collection in patients with multiple myeloma treated with anti-CD38 monoclonal antibodiesПодробнее

Anti CD38, SLAMF-7 and BiTE immunotherapy: Are immune therapeutics ready for the frontline?Подробнее

Advances in monoclonal antibody therapy for multiple myelomaПодробнее

Dr. Angela Dispenzieri Discusses Anti-CD38 Monoclonal Antibodies in MyelomaПодробнее

Mechanisms of action of CD38 antibodies in myelomaПодробнее